You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Enzo shareholder issued an open letter stating its concern about the company's stock performance.
Enzo's fiscal first quarter revenues grew 2 percent year over year to $25.2 million, driven by an 8 percent spike in clinical laboratory services.
It's the first approved test to feature the firm's proprietary AmpiProbe nucleic acid amplification and detection platform.
Affymetrix will pay Enzo $10 million to settle litigation Enzo brought against the company over a method for nucleic acid analysis.
As part of a settlement deal, Siemens will pay Enzo an upfront fee of $9.5 million and potentially up to $5 million in licensing royalties.
The US District Court in Delaware has adopted Enzo's interpretation of patent language and rejected the defendants' argument to invalidate a key patent.
Luminex will pay Enzo Biochem $7.1 million to settle a lawsuit alleging infringement of patents for oligonucleotides and solid supports for fixed nucleic acids.
An 8 percent increase in Enzo Clinical Lab revenues was offset by a 9 percent decrease in Life Sciences revenues.
Hologic said in its Form 10-Q that Enzo sued the firm in March alleging infringement of a patent related to labeled nucleotides for use as diagnostic tools.
The appeals court reversed in part an earlier decision by aUSdistrict court that resulted in a $61 million award to Enzo, and remanded the case back to the district court.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.